Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $280.00 Price Target at JPMorgan Chase & Co.
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective boosted by stock analysts at JPMorgan Chase & Co. from $272.00 to $280.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of […]
Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) had its price objective boosted by stock analysts at JPMorgan Chase & Co. from $272.00 to $280.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. JPMorgan Chase & Co.‘s target price points to a potential upside of […]
